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Abstract 
Background: The association between cigarette smoking and psychosis remains 
unexplained, but could relate to causal effects in both directions, confounding by 
socioeconomic factors such as ethnicity, or use of other substances, including cannabis. Few 
studies have evaluated the association between cigarettes and psychotic experiences (PEs) 
in diverse, inner-city populations, or relationships with number of cigarettes consumed.  
Methods: We assessed associations and dose-response relationships between cigarette 
smoking and PEs in a cross-sectional survey of household residents (n=1680) in South East 
London, using logistic regression to adjust for cannabis use, other illicit substances, and 
socioeconomic factors, including ethnicity.  
Results: We found association between any PEs and daily cigarette smoking, which 
remained following adjustment for age, gender, ethnicity, cannabis and use of illicit stimulant 
drugs (fully adjusted OR: 1.47; 95%CI: 1.01, 2.15). Fully-adjusted estimates for the 
association, and with number of PEs, increased with number of cigarettes smoked daily, 
implying a dose-response effect (P=0.001 and <0.001, respectively). Odds of reporting any 
PEs in ex-smokers were similar to never-smokers.   
Conclusions: In this diverse epidemiological sample, association between smoking and PEs 
was not explained by confounders such as cannabis or illicit drugs. Daily cigarette 
consumption showed a dose-response relationship with the odds of reporting PEs, and of 
reporting a greater number of PEs. There was no difference in odds of reporting PEs between 
ex-smokers and never-smokers, raising the possibility that the increase in PEs associated 
with smoking may be reversible. 
Introduction 
 
The search for environmental causes for psychosis(Dean and Murray, 2005) in the last three 
decades has included factors that can be experienced after childhood, for example migration 
and the use of substances(Morgan et al., 2010). Investigations into the possible causal 
effects of cannabis have featured prominently in research into substances, with a meta-
analysis estimating that cannabis users experienced nearly three times the odds of having 
psychosis compared to non-users (OR: 2.93, 95%CI: 2.36,3.64,(Semple et al., 2005).  More 
recently, other drugs have been examined, most notably tobacco. 
 
There is a strong positive association between smoking cigarettes and psychotic disorders(de 
Leon and Diaz, 2005). The most recent meta-analysis of smoking as a risk factor for 
psychosis estimated the odds ratio for daily smoking to be around 3, based on eleven case-
control studies, and the relative risk, from five prospective studies, to be approximately 
2(Gurillo et al., 2015). The positive association between tobacco smoking and psychotic 
illnesses has a number of candidate explanations. These include: 
 
a. self-medication(Kumari and Postma, 2005), for example of psychiatric 
symptoms(Smith et al., 2002), cognitive deficits(Barr et al., 2008, Sacco et al., 2005, 
George et al., 2002), or adverse effects of psychiatric drugs(Goff et al., 1992),  
b. shared genetic liability to both smoking and psychoses(Lyons et al., 2002, Smith et 
al., 2008, Chen et al., 2016),  
c. a causal effect of smoking on schizophrenia(Kendler et al., 2015, Weiser et al., 
2004),  
d. a reverse causal effect- mental health problems could result in people who smoke 
being less likely to quit, for example because of more severe nicotine dependence or 
more limited access to smoking cessation treatment(Szatkowski and McNeill, 2014), 
and  
e. confounding by other drug use – people who smoke are more likely to take other 
drugs, including cannabis and stimulants(Morral et al., 2002, Regier et al., 1990), 
which may be causally associated with psychosis(Large et al., 2011, Semple et al., 
2005). 
 
In a recent prospective study, Kendler and colleagues found that smoking was associated 
with later schizophrenia in two Swedish cohorts, after accounting in the design for shared 
familial factors between people who developed schizophrenia and those who did not(Kendler 
et al., 2015). Heavy smokers in discordant monozygotic twin pairs were around 1.7 times 
more likely to develop psychosis compared to the non-smoking twin, suggesting that genetic 
factors do not completely explain the relationship between smoking and later psychosis. 
Strengths of association were not affected by specifying different buffer periods between 
smoking assessment and first diagnosis, implying that the association did not arise as a result 
of people smoking as part of the psychosis prodrome.  
 
It is increasingly argued that psychotic disorders represent the extreme end of a 
phenomenological continuum of psychotic experiences (PEs) which extend into the general, 
non-clinical population(Johns et al., 2004, Johns and Van Os, 2001, Linscott and van Os, 
2013). However, although observational data from a number of sources have indicated high 
smoking prevalence in people with mental disorders (Royal College of Psychiatrists 
(RCPSYCH, 2013 ), few studies have addressed the question of whether tobacco smoking is 
associated with PEs in the general population(Van Gastel et al., 2013, Gage et al., 2014). 
Furthermore, the extent to which any association is explained by confounding by cannabis or 
socioeconomic factors is unclear.  
 
This study examined the association between cigarette smoking and PEs in a representative 
population-based sample of South London. 
 
Our objectives were to: 
 
1. Estimate the association between smoking and PEs and between smoking and the 
number of PEs reported, taking into account possible confounding by cannabis, 
stimulant use and ethnicity, and  
2. Test for a linear trend in the odds of reporting PEs with quantity of cigarettes smoked 
per day.  
 
 
Methods 
 
Sample: 
The South East London Community Health study (SELCoH(Hatch et al., 2011) is a 
representative household survey of South East London residents collected in 2008-2010. The 
analytic sample consisted of 1698 people, residing in 1075 households, collected through 
random sampling of a postcode address file, who were interviewed by lay researchers. 
Respondents were between the ages of 16 and 90 years of age.  Of 2359 people eligible 
within participating households, 1698 (71.9%) participated.  
 
Psychotic experiences:  
The rating scale used for the assessment of PEs was the Psychosis Screening Questionnaire 
(PSQ(Bebbington and Nayani, 1995). The PSQ is a self-report questionnaire designed to be 
administered by lay interviewers for use in large-scale epidemiological studies, for the 
purpose of screening respondents for possible psychotic disorder. It is a five-item 
questionnaire that assesses different positive psychotic symptom domains experienced in the 
previous year. These comprise: hypomania, strange experiences, persecutory experiences, 
auditory hallucinations, and thought interferences. Each domain contains an initial “probe” 
item, which is followed by secondary questions. Because the present study was focused on 
non-affective psychosis, responses to the hypomania item were not examined. Endorsement 
of PEs was defined as positive response to items in the four remaining domains. This 
approach was consistent with a previous analysis of PEs originating from these data(Morgan 
et al., 2014).  Information on the number of domains endorsed was also available. The PSQ 
displays good correspondence with psychosis items on the Schedules for Clinical 
Assessment in Neuropsychiatry(Bebbington and Nayani, 1995)  and has seen frequent use in 
population studies(e.g.(Bebbington et al., 2004, Johns et al., 2004, Johns et al., 2002) 
 
Sociodemographic and clinical measures 
Data on age, gender, employment status (employed, unemployed, student, other), ethnicity 
(White, Black Caribbean, Black African, Asian, and other), marital status (single, 
married/cohabiting, divorced/separated, and widowed), social class (measured by the NS-
SEC), a composite score of general cognitive ability (details available in Mollon et al. (2016), 
and highest educational attainment (no qualifications, GCSE, A level, and degree level or 
above) were available. The presence of symptoms of a common mental disorder in the 
previous two weeks was defined based on responses to the CISR (Clinical Interview 
Schedule, Revised(Lewis and Pelosi, 1990)), with a cut-off score of twelve(Lewis et al., 
1992).  
 
Measurement of cigarette smoking: 
Information on cigarette smoking analysed in this study was collected from SELCoH 
participants at four levels: the category of “never smoked” was based on answering “no” to 
the question: “have you ever smoked a cigarette?”. Ex-smokers were defined as those 
answering “yes” to the question: “have you ever smoked a cigarette?” and then answering 
“no” to the question: “do you smoke cigarettes at all nowadays?”. Sporadic smoking was 
based on answering “yes” to the question: “have you ever smoked a cigarette?”, then “yes” to 
the question: “do you smoke cigarettes at all nowadays?”, and then reporting a zero daily 
cigarette intake when asked: “about how many cigarettes a day do you usually smoke?”. 
Finally, daily smokers were defined by answering positively to both prior questions and 
providing an estimate of the number of daily cigarettes smoked. All participants defined as 
daily smokers were therefore current smokers.  
 
Ascertainment of cannabis use: 
Participants were asked about cannabis use frequency and categorised into the following 
groups: never used, use less frequently than once a week, use more than once a week but 
less than daily, and use daily.  
 
Evaluation of stimulant substance use: 
Participants reported use of amphetamines, ecstasy, cocaine and crack use; all were 
combined into a single variable with three levels - never used, use but not in the previous 
year, and use in the previous year. All models which adjusted for substance misuse included 
this three level variable.  
 
Analysis: 
All analyses were carried out in STATA 14(Stata, 2014) and took account of non-response 
weights and clustering of responses by household. Inverse probability weights(Pickles et al., 
1995) were calculated from logistic regression models for non-response of an eligible 
individual within households. Predictor variables for non-response were selected for inclusion 
in the final weights model based on strength of statistical evidence (p-values of less than 
0.05) and whether the selected weighting scheme reproduced the means and prevalences of 
participants with complete data.  The final prediction model contained effects of age and 
gender. Categorical descriptions of the sample by PEs were inspected. Univariate 
associations between PE status and cigarette smoking, stimulants, and sociodemographic 
variables (age, gender, and ethnicity) were evaluated and presented. Multivariate models 
were used to assess and account for confounding. Age and gender were included in all 
models. Covariates whose inclusion in the model did not deviate the association between 
PEs and daily cigarette smoking by more than 10% of the unadjusted odds ratio were 
discarded(Greenland et al., 2016). This left age, gender, and ethnic group as covariates in 
modelling, alongside stimulant and cannabis use as potential confounders of primary interest. 
In particular, neither the inclusion of general cognitive ability, marital status, employment 
status, social class, nor educational attainment altered estimates sufficient for their inclusion. 
Having identified evidence of strong negative confounding by ethnicity, we explored the 
association between ethnic group and smoking, presented in table 7 of the supplementary 
material to this paper. Also presented as supplementary material are descriptive data on the 
overlap between cigarette smoking and use of cannabis, and of stimulants. Modification of the 
association between current smoking and reporting any PEs by age, cannabis use and 
common mental disorder was tested by fitting multiplicative interaction terms for smoking 
status by age, cannabis use, and common mental disorder in fully adjusted models. Ordinal 
logistic regressions were used to assess the association between smoking status and number 
of PEs (range from 0-4). Finally, we examined the possibility of a dose-response relationship 
by assessing linear trends in the association between the number of cigarettes smoked and 
a. the odds of reporting any PEs (from logistic regression models), and b. the odds of 
reporting one further PE (from ordinal logistic regression models).  
 
 
 
Results 
 
After excluding participants with missing data on the modelled variables, 1680 survey 
participants remained for analysis. Sociodemographic and substance use associations with 
PEs are shown in table 1. PEs were more frequently reported by younger participants, and 
those with Black Caribbean and Black African ethnic status. Cannabis, ecstasy, cocaine and 
other stimulants were associated with PEs. The estimate for crack cocaine, whilst indicating a 
possible strong association, was imprecise and not statistically significant, as its use was 
seldom reported. Cannabis use frequency was strongly associated with use of stimulant 
drugs (see supplementary material, table 6). There was an association between PEs and 
daily, but not sporadic or past, cigarette smoking. Multivariate models for the odds of 
reporting any PEs are show in table 2: when sociodemographic variables were included in the 
model, the estimate increased, indicating positive confounding by age, gender, and ethnicity. 
Further adjustment for cannabis frequency attenuated the odds ratio for daily smoking on 
PEs. Finally, adjustment for stimulant use (recent and in the lifetime) modestly reduced the 
association. No statistical evidence was found for differences in the association between 
current smoking and the odds of reporting PE within different age groups, or at different levels 
of cannabis use.  
 
We found strong statistical evidence for a dose-response relationship between the number of 
cigarettes smoked and the odds of reporting any PEs, and the reporting of a greater number 
of PEs, in adjusted models.  On average an increase in daily cigarette consumption from 0 to 
1-9, from 1-9 to 10-19, or 10-19 to 20 or more, was accompanied by a by a 1.04 increase in 
the overall relative odds of reporting any PEs (95%CI: 1.02,1.07; table 3) and a 1.58 fold 
increase in the relative odds of reporting one further PE (95%CI: 1.32, 1.90; table 3).  
 
Daily smoking was associated not only with an increased odds of reporting PEs, but also with 
increasing number of PEs, although this estimate lost precision after adjusting for stimulant 
use (fully adjusted OR: 1.55, 95%CI: 0.98, 2.47, table 4). The most common PE was strange 
experiences (6.05%), followed by auditory hallucinations (3.87%), then persecutory 
experiences (3.27%), with thought interferences the least common PE (1.32%). Individual 
types of PE were associated with daily smoking, with precise estimates for strange 
experiences, but not for the other symptoms. In fully adjusted models, associations remained 
for each symptom, but lost precision. On account of the association between PEs and other 
symptoms of mental disorder, we estimated associations of PEs with smoking pattern by 
common mental disorder, shown in table 5 of the supplementary material. No statistical 
evidence was found for variation in effect estimates by common mental disorder, although 
this test lacked power. Because of the association between ethnicity and PEs, and the 
attenuation in estimates observed when it was included in regression models, we described 
the association between ethnicity and smoking, reported in table 7 (included in supplementary 
material): all non-White ethnic groups had lower proportions of reported daily, ex-, and 
sporadic smoking compared to the White reference group (p<0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
Summary of findings 
We found evidence of a cross-sectional association between daily cigarette smoking, but not 
ex-smoking, and PEs in a sample of household residents in South East London. The 
association was not explained completely by cannabis use frequency, or by use of stimulant 
drugs, or by ethnicity (ethnicity was strongly associated with daily smoking, see 
supplementary material, table 7). There was an increasing strength of association observed 
by number of cigarettes smoked, and increased cigarette consumption predicted a greater 
number of PEs. We did not find statistical evidence for interaction of smoking with age, 
cannabis use, or with symptoms of common mental disorder.  
 
Previous literature 
Smoking is a crucial, potent, and modifiable cause of morbidity and mortality in the 
UK(Matcham et al., 2017). Although the number of people who smoke in the UK is falling, 
(Action on Smoking and Health( 2015)), this decline is not reflected in people with mental 
illness (National Centre for Social Research, (2010)); and data from the Health Survey for 
England suggests that smoking may be declining more slowly in people with mental health 
problems compared to those without(Szatkowski and McNeill, 2014). Therefore, identifying 
the mechanisms by which smoking and mental illness are associated could be beneficial for 
public health.  
 
Our findings, that PEs and daily smoking are associated, are consistent with a small body of 
literature suggesting that smoking is more common in people with sub-clinical PEs than the 
rest of the general population. Firstly, van Gastel et al(2013) reported an analysis of an 
internet survey, finding that the cross-sectional association between scores on the 
Community Assessment of PEs and daily smoking for the past month remained apparent 
despite accounting for cannabis use and for a group of other confounders. Secondly, smokers 
were 1.3 times more likely to report PEs in the World Health Surveys compared to non-
smokers, after adjustments, suggesting the association is consistent across national 
settings(Koyanagi et al., 2016). Thirdly, Wiles et al(2006) reported association between 
smoking and PEs in the 2007 UK Adult Psychiatric Morbidity Surveys, but found that the 
crude association was strongly attenuated by adjustment for cannabis, general cognitive 
ability and marital status. Fourthly, Saha et al found that daily smoking was associated with 
reporting delusion-like experiences in an Australian household survey(2011), after adjusting 
for a broad range of confounders.  Fifth, in an analysis of prospective data from the Avon 
Longitudinal Study of Parents and Children, Gage et al(2014) reported that smoking at aged 
16 was predictive of PEs at 18, after accounting for cannabis use frequency and a range of 
early and mid-life confounders. Overall, few previous studies have assessed dose-response 
relationship with number of cigarettes smoked or by number of PEs reported, and few studies 
have adjusted for cannabis use in detail, for example, by including cannabis use frequency in 
statistical models.  
 
How our results fit in 
Our results, from a highly socioeconomically and ethnically diverse sample, are consistent 
with the previous literature suggesting the cross-sectional association between cigarette 
smoking and PEs is not fully explained by cannabis use, the use of stimulant drugs, or 
confounding by demographic or socioeconomic status, particularly by ethnic group. 
Furthermore, we present evidence that the relationship between odds of reporting any PEs, 
and a greater number of PEs is related to the number of cigarettes smoked per day. Finally, 
we extend previous literature by presenting evidence that daily smoking predicts the reporting 
of more PEs on a continuous scale. We also found no evidence of association between PEs 
and being an ex-smoker, implying that our analysis did not suffer from confounding by non-
time-varying characteristics, such as unadjusted sociodemographic factors. The finding of no 
association between PEs and ex-smoking is consistent with other literature suggesting that 
mental health improves following smoking cessation(Taylor et al., 2014) raising the possibility 
that the increase in PEs associated with smoking may be reversible. Our results are also 
consistent with smoking being a more persistent behaviour in people with PEs compared to 
those without, and fit with some evidence that people with psychosis who smoke tend to have 
more severe positive symptoms and more limited social adjustment(Barnes et al., 2006, 
Krishnadas et al., 2012). 
 
Strengths and limitations 
This was a cross sectional study and these associations could be explained by smoking 
occurring after PEs. Measurement of smoking, PEs, and cannabis use were by self-report in 
the same survey, and some way of confirming this information in independent data would 
have improved the validity of the study. Strong collinearity between exposure and a 
confounder limits the ability of regression methods to correctly adjust for confounding - in this 
study, the close overlap between cannabis use and cigarette smoking(Amos et al., 2004) 
might not have fully allowed for the identification of separate effects for these two 
factors(Greenland et al., 2016, Gage et al., 2014). There were no data on the persistence or 
timeframe of PEs, further limiting inference. Although we were able to adjust estimates for 
stimulant use, this was in the form of an aggregated variable across four different stimulants, 
leaving open the possibility of residual confounding by the use of individual stimulants. 
However, despite these limitations to the data, the study did allow the assessment of this 
association in an urban, diverse population with relatively high levels of cannabis and 
stimulant use, in contrast to previous studies.  The generalizability of our results to the rest of 
the UK population could be limited. However, a previous study based on this data suggested 
similarity in the distributions of age, gender, economic activity and ethnicity to the overall 
English population recorded in the UK Census(Hatch et al., 2011). We found evidence that 
ethnic group was strongly related to the probability of daily smoking, in accordance with other 
studies(Best et al., 2001, McCambridge and Strang, 2005, Wanigaratne et al., 2003), and 
adjusted for it as a possible confounder (see supplementary material, table 7).  
 
Conclusions 
The association between PEs and smoking is apparent in a highly diverse population with 
relatively prevalent use of cannabis and stimulant drugs. The linear relationship between 
cigarette consumption and odds of reporting PEs requires urgent explanation in longitudinal 
studies and diverse populations.  
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Table 1. Counts and survey-weighted univariate associations between PEs and each 
variable used in this study, based on the analytic sample of 1680.  
 Number 
in each 
category 
Number 
reporting PEs 
in category (%) 
PE Odds 
Ratio 
95% CI  
Age    
 16-24 356 85(23.88) Reference  
 25-34 401 69(17.21) 0.69 0.48, 0.99 
35-44 334 64(19.16) 0.76  0.52, 1.11 
45-54 259 57(22.01) 0.91 0.62, 1.34 
55-64 157 25(15.92) 0.61 0.37, 1.00 
65+ 173 19(10.40) 0.37  0.21, 0.66 
Gender   
  Male 730 147(20.14) Reference  
 Female 950 171(18.00) 0.86 0.68, 1.09 
Ethnicity   
  White 1045 170(16.27) Reference  
 Black Caribbean 143 45(31.47) 2.28 1.51, 3.47 
Black African 229 51(22.27) 1.46 1.01, 2.10 
Asian 62 8(12.90) 0.71 0.35, 1.44 
Other 201 44(21.89) 1.43 0.98, 2.06 
Smoking pattern   
  Never smoker 513 84(16.37) Reference  
 Ex-smoker 448 77(17.19) 1.06  0.75, 1.49 
Sporadic smoker 297 47(15.82) 0.97 0.65, 1.44 
Daily smoker 422 110(26.07) 1.76 1.27, 2.42 
Crack use   
  Never 1642 300(18.27) Reference  
 Yes, not in the last year 34 16(47.06) 3.82 1.93, 7.61 
Yes, in the last year 4 2(50.00) 4.04 0.56, 28.91 
Ecstasy use   
  Never 1383 245(17.72) Reference  
 Yes, not in the last year 215 50(23.26) 1.42 1.00, 2.02 
Yes, in the last year 82 23(28.05) 1.78 1.05, 3.02 
Amphetamine use   
  Never 1409 247(17.53) Reference  
 Yes, not in the last year 241 61(25.31) 1.59  1.16, 2.18 
Yes, in the last year 30 10(33.33) 2.19 1.04, 4.63  
Cocaine use   
  Never 1308 225(17.20) Reference  
 Yes, not in the last year 238 55(23.11) 1.45  1.03, 2.04 
Yes, in the last year 134 38(28.36) 1.87 1.22, 2.84 
Any stimulant use     
 Never 1234 204(16.53) Reference  
 Yes, not in the last year 287 69(24.04) 1.80  1.25, 2.61  
Yes, in the last year 159 45(28.30) 1.94 1.31, 2.88 
Cannabis use   
  Never 1502 255(16.98) Reference  
 Less than once a week 74 21(28.38) 1.89 1.10, 3.22 
More than once a week 
but less than daily 57 22(38.60) 3.00 1.76, 5.16 
Daily 47 20(42.55) 3.49 1.89, 6.45 
Total 1680 318(18.93) - - 
Table 2. Odds ratio estimates for smoking pattern on PEs from survey weighted logistic regression. All 
models based on 1680 participants. Age was adjusted for as a continuous variable.  
 Model I: 
Unadjusted 
 Model II: Model I 
adjusted for age, 
gender, and 
ethnicity 
 Model III: Model 
II further 
adjusted for 
frequency of 
cannabis use 
 Model IV: 
Model III further 
adjusted for 
stimulant use* 
      OR 95% CI  OR 95% CI    OR 95% CI   OR 95% CI 
Never smoker  Reference     Reference    Reference   Reference 
Ex-smoker  1.06   0.75, 1.49   1.40 0.96, 2.05   1.30  0.89, 1.90  1.25  0.78, 1.82  
Sporadic 
smoker 
  0.97   0.65, 1.44   1.09 0.72, 1.66    1.05  0.69, 1.59  1.03  0.68, 1.58  
Daily smoker  1.76   1.27, 2.42   2.05  1.44, 2.92    1.66  1.15, 2.4  1.47 1.01, 2.15 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Odds ratio (OR) estimates for the association between a. any PEs (upper panel) and b. the number of 
PEs (lower panel, reflecting the increase in relative odds for one more PE) with quantity of cigarettes smoked 
per day. Based on overall analytic sample of 1680. Test statistics (T) are from survey-weighted logistic 
regression models. 
Daily 
cigarettes 
smoked 
Model I: Unadjusted Model II: Model I 
adjusted for age, 
gender, and ethnicity 
Model III: Model II 
further adjusted for 
frequency of 
cannabis use 
Model IV: Model III 
further adjusted for 
stimulant use* 
Any PE OR 95% CI OR  95% CI OR  95% CI  OR       95% CI 
0 Reference Reference Reference Reference 
1-9 1.51 1.06, 2.15 1.38 0.96, 2.00 1.15 0.78, 1.69 1.05 0.71, 1.56 
10-19 2.26 1.54, 3.31 2.36 1.59, 3.49 1.98 1.31, 2.98 1.88 1.24, 2.84 
20 or more 2.13  1.24, 3.67 2.54 1.46, 4.43 2.20 1.25, 3.89 2.04 1.15, 3.62 
 T for linear trend=4.19 
P<0.001 
T for linear trend=4.76 
P<0.001 
T for linear trend=3.66 
P<0.001 
T for linear trend=3.32 
P=0.001 
Number of 
PEs 
    
0 Reference Reference Reference Reference 
1-9 1.65 1.03,2.64 1.62 1.00,2.64 1.39 0.85,2.29 1.36 0.83,2.22 
10-19 2.52 1.61,3.94 2.97 1.85,4.76 2.50 1.52,4.11 2.37 1.43,3.91 
20 or more 4.17 2.29,7.62 5.53 3.03,10.09 4.70 2.50,8.83 4.32 2.29,8.15 
 T for linear trend=3.32 
P=0.001 
T for linear trend=6.52 
P<0.001 
T for linear trend=5.30 
P<0.001 
T for linear trend=4.98 
P<0.001 
 
 
 
Table 4. Models comparing daily smokers to never smokers for an increase in number of PEs, and for separate types of 
psychotic experience. All models based on 1680 participants. Estimates for ex-smokers and sporadic smokers are not 
presented. 
 
OR(95%CI) for 
an increase of 
one psychotic 
experience 
OR(95% CI) for 
auditory 
hallucinations  
OR(95% CI) for 
thought 
interferences  
OR(95% CI) for 
persecutory 
experiences  
OR(95% CI) for 
strange 
experiences  
Number reporting this 
symptom (% of sample) 
 65(3.88) 22(1.32) 55(3.30) 100(6.05) 
Model I: Unadjusted 1.76(1.19,2.59) 1.68(0.91,3.08) 2.17(0.72,6.57) 1.45(0.76,2.77) 2.02(1.19,3.42) 
Model II: Model I further 
adjusted age, gender and 
ethnicity 
2.12(1.37,3.26) 2.14(1.05,4.37) 4.65(1.53,14.09) 1.62(0.76,3.46) 2.39(1.37,4.18) 
Model III: Model II further 
adjusted for cannabis use 
1.70(1.09, 2.66) 1.78(0.85,3.72) 3.37(1.04,10.91) 1.32(0.59,2.96) 1.89(1.05,3.4) 
Model IV: Model III further 
adjusted for stimulant use* 
1.55 (0.98, 2.47) 1.56(0.72,3.39) 3.25(0.97,10.87) 1.14(0.51,2.58) 1.74(0.95,3.18) 
  
 
